Skip to main content

Table 5 Synopsis of selected phase II chemotherapy trials performed for recurrent GBM

From: Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients

Reference Intervention Pts. (n) chemo-naïve (%) PFS6 mo (%) PFS (weeks)
Brandes (2004) [23] BCNU ± re-resection 40 100 17.5 13.3
Fine (2003) [25] BCNU + thalidomide 38 50 27 14.9
Prados (2004) [26] BCNU + TMZ (single dose) 38 89.5 21 11
Brandes (2004) [24] BCNU + irinotecan 42 0 30.3 17
Yung (2000) [46] TMZ (5/28) vs. procarbazine 112 35 21 vs. 8 12.4
Brada (2001) [47] TMZ (5/28) 128 29 18 8
Brandes (2002) [48] TMZ (5/28) 42 0 24 11.7
Chang (2004) [49] TMZ (5/28) 142 56 18 10
Wick (2007) [50] TMZ (7/14) 64 36 43.8 24
Perry (2010) [51] TMZ (continuous) 91 NR 23.9 7–15
Kappelle (2001) [52] PCV 63 68.2 29 13
Wong (1999) [53] historical controls 225 NR 15 9
  1. ND not determined, NR not reported